Gastrofensin AN 5 free base

Gastrofensin AN 5 free base, a 4-phenyl-tetrahydroisoquinoline derivative, is an antiulcer agent.

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

Gastrofensin AN 5 supresses the formation of ulcers in all experimental models. From the broad pharmacological studies of Gastrofensin AN 5 on this model it can be seen that even a dose of 0.100 mg/kg has a high antiulcer activity. The increase of the dose leads to a regular increase of the antiulcer activity, the highest suppression of the ulcer index being reaches at a dose of 1 mg/kg (86.15%). The comparative studies with Ranitidine and Cimetidine on the same experimental models of gastric ulcers show that Gastrofensin AN 5 possesses an antiulcer activity many times higher than that of the above-mentioned drugs[1].

[1]. Ivanova N, et al. A new class of antiulcer drugs. I. Antiulcer effect of AN5, a 4-phenyl-tetrahydroisoquinoline derivative, on different experimental models of ulcer in rats. Methods Find Exp Clin Pharmacol. 1990 Jul-Aug;12(6):401-10.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline